S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91

KemPharm Stock Forecast, Price & News

+0.19 (+2.37%)
(As of 12/2/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
494,738 shs
Average Volume
1.65 million shs
Market Capitalization
$290.32 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive KMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for KemPharm and its competitors with MarketBeat's FREE daily newsletter.

KemPharm logo

About KemPharm

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.


KemPharm, Inc. (NASDAQ:KMPH) Chairman Buys $11,820.00 in Stock
November 30, 2021 |  americanbankingnews.com
KemPharm (NASDAQ:KMPH) Earns Hold Rating from HC Wainwright
November 12, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$13.29 million
Book Value
($14.64) per share


Net Income
$-12.76 million
Pretax Margin




Free Float
Market Cap
$290.32 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.77 out of 5 stars

Medical Sector

862nd out of 1,391 stocks

Pharmaceutical Preparations Industry

411th out of 669 stocks

Analyst Opinion: 2.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

KemPharm (NASDAQ:KMPH) Frequently Asked Questions

Is KemPharm a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for KemPharm in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KemPharm stock.
View analyst ratings for KemPharm
or view top-rated stocks.

When is KemPharm's next earnings date?

KemPharm is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for KemPharm

How were KemPharm's earnings last quarter?

KemPharm, Inc. (NASDAQ:KMPH) issued its quarterly earnings results on Wednesday, November, 10th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.02. KemPharm had a positive trailing twelve-month return on equity of 8.82% and a negative net margin of 37.66%. During the same quarter in the previous year, the business posted ($0.64) EPS.
View KemPharm's earnings history

What price target have analysts set for KMPH?

2 brokers have issued twelve-month target prices for KemPharm's stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate KemPharm's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 21.7% from the stock's current price.
View analysts' price targets for KemPharm
or view top-rated stocks among Wall Street analysts.

Who are KemPharm's key executives?

KemPharm's management team includes the following people:
  • Travis C. Mickle, Chairman, President & Chief Executive Officer
  • Christal M. M. Mickle, Vice President-Operations & Product Development
  • R. LaDuane Clifton, Chief Financial Officer, Secretary & Treasurer
  • Sven Guenther, Executive Vice President-Research & Development
  • Timothy J. Sangiovanni, Vice President & Controller

What other stocks do shareholders of KemPharm own?

When did KemPharm IPO?

(KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

What is KemPharm's stock symbol?

KemPharm trades on the NASDAQ under the ticker symbol "KMPH."

Who are KemPharm's major shareholders?

KemPharm's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.57%), Geode Capital Management LLC (1.39%), Janney Montgomery Scott LLC (0.79%), Goldman Sachs Group Inc. (0.48%), Renaissance Technologies LLC (0.47%) and Citadel Advisors LLC (0.00%). Company insiders that own KemPharm stock include David S Tierney, Gordon K Johnson, R Laduane Clifton, Richard W Pascoe, Samuel J Braun, Timothy J Sangiovanni and Travis C Mickle.
View institutional ownership trends for KemPharm

Which institutional investors are selling KemPharm stock?

KMPH stock was sold by a variety of institutional investors in the last quarter, including California State Teachers Retirement System, Jane Street Group LLC, Sculptor Capital LP, Alliancebernstein L.P., New York State Common Retirement Fund, Belvedere Trading LLC, BlackRock Inc., and HAP Trading LLC.
View insider buying and selling activity for KemPharm
or view top insider-selling stocks.

Which institutional investors are buying KemPharm stock?

KMPH stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Renaissance Technologies LLC, Marshall Wace LLP, Citadel Advisors LLC, Stratos Wealth Partners LTD., Martingale Asset Management L P, Strategic Asset Management LLC, and Two Sigma Advisers LP. Company insiders that have bought KemPharm stock in the last two years include David S Tierney, Gordon K Johnson, R Laduane Clifton, Richard W Pascoe, Samuel J Braun, Timothy J Sangiovanni, and Travis C Mickle.
View insider buying and selling activity for KemPharm
or or view top insider-buying stocks.

How do I buy shares of KemPharm?

Shares of KMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is KemPharm's stock price today?

One share of KMPH stock can currently be purchased for approximately $8.22.

How much money does KemPharm make?

KemPharm has a market capitalization of $290.32 million and generates $13.29 million in revenue each year.

How many employees does KemPharm have?

KemPharm employs 22 workers across the globe.

What is KemPharm's official website?

The official website for KemPharm is www.kempharm.com.

Where are KemPharm's headquarters?

How can I contact KemPharm?

KemPharm's mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The specialty pharmaceutical company can be reached via phone at (321) 939-3416, via email at [email protected], or via fax at 319-665-2577.

This page was last updated on 12/3/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.